Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).
Critère d'inclusion
- Dry Eye Syndromes,Keratoconjunctivitis Sicca